ClinicalTrials.gg
TerminatedNCT03440437Updated Jul 1, 2025

A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

A Phase 1/2 interventional study of FS118 and Paclitaxel in Advanced Cancer, Metastatic Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by invoX Pharma Limited. Terminated at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by invoX Pharma Limited (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Business Decision

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Enrollment
615th of 1,863
80 · median 43
Started
2018
with 73 others
Phase 1/2
267 of 2,054
63 open now
Registered
1,230th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 615th largest by enrollment of the 1,863 interventional ones that give a count, is one of 74 that started in 2018, is one of 267 in phase 1/2, and was the 1,230th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted in adult participants diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118. This is a Phase 1/2, multi-center, open-label, multiple-dose, first-in-human study, designed to systematically assess safety and tolerability, to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS118 in participants with advanced tumors and to determine the efficacy of FS118 in participants with squamous cell carcinoma of the head and neck (SCCHN) as monotherapy and in combination with paclitaxel. In addition to safety, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy will also be assessed.

03

Conditions studied

  • Advanced Cancer
  • Metastatic Cancer
  • Squamous Cell Carcinoma of Head and Neck

Keywords

  • FS118
  • Immuno-oncology
  • bispecific antibody
  • check-point inhibitor
  • dose escalation
  • cohort expansion
  • PK
  • PD
  • biomarker
  • LAG-3
  • PD-L1
  • SCCHN
  • F-star
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • Age ≥18 years;
  • Participants with confirmed, locally advanced, unresectable, or solid tumors that progressed while on or after /PD-L1 containing therapy;
  • ;
  • (ECOG) Performance Status ≤1;
  • estimated to be at least 3 months;
  • Highly effective ;
  • Willing and able to provide written .

Expansion cohort only:

  • Histologically and/or cytologically confirmed recurrent/metastatic (R/M) SCCHN that is not amenable to curative therapy by surgery or radiation;
  • Only 1 prior anti-PD-1 or anti-PD-L1 therapy and documented PD-L1 scoring ≥1% by combined positive score or tumor proportion score as part of their treatment;
  • An anti-PD-1 or anti-PD-L1 treatment regimen must be the last prior therapy before study enrollment, following no more than 2 prior systemic regimens for R/M SCCHN;
  • Acquired resistance to an anti-PD-1- or anti-PD-L1-containing therapy;
  • The participant agrees to undergo a pre-treatment and on-treatment core or excisional and the biopsy procedure is not judged to be high risk by the Investigator.

Exclusion criteria

Exclusion Criteria:

All participants:

  • Participant is deemed at high risk of fatal outcome in case of COVID-19;
  • Participants with a history of COVID-19 and have not provided a negative test for SARS CoV-2 infection within 28 days of the planned first dose date with FS118;
  • Prior therapy: Received systemic anti-cancer therapy within 28 days or 5 half-lives, of the first dose of study drug, or prior treatment with a LAG-3 inhibitor;
  • Participants with active or documented history of disease;
  • History of uncontrolled intercurrent illness;
  • Known infections;
  • Uncontrolled , primary CNS tumors, or solid tumors with CNS metastases as only ;
  • Prior history of or active interstitial lung disease or pneumonitis, encephalitis, seizures, severe immune related adverse events with prior /PD-L1 containing treatments;
  • Significant cardiac abnormalities;
  • Significant laboratory abnormalities;
  • Intolerance to the product or its , or any condition that would significantly impair and/or prohibit the participants's participation in the study, as per the Investigator's judgment.

Expansion cohort only:

  • Participant has nasopharynx or thyroid primary tumor site;
  • History of severe immune-related toxicity during the prior treatment with checkpoint inhibitors.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    FS118 weekly

    The initial cohorts will enroll sequentially as single-participant cohorts. If no DLT or ≥Grade 2 study drug related adverse event is observed, then dosing will proceed in a 3+3 design followed by an expansion cohort of participants with SCCHN and an expansion SCCHN cohort in combination with Paclitaxel.

    Drug: FS118 · Drug: Paclitaxel

Interventions

  • DrugFS118

    Dosing of participants will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (i.e., immune confirmed progressive disease), unacceptable toxicity, or discontinuation.

  • Dosing on Days 1, 8 and 15 of each 28 day cycle in combination with FS118 given on days 1, 8, 15 and 22 of each 28 day cycle.

06

What researchers measure

Primary outcomes

  1. Dose escalation: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)

    Incidence, severity and duration of adverse events will be assessed by CTCAEv4.03

    Time frame: 12 months

  2. Dose escalation: Serum Concentration vs time profile of FS118

    Blood samples for serum PK analysis will be obtained (concentrations measured in mcg/mL)

    Time frame: 7 months

  3. Dose escalation: Maximum Serum Concentration of FS118

    Blood samples for serum PK analysis will be obtained (Cmax measured in mcg/mL)

    Time frame: 7 months

  4. Dose escalation: Time to reach maximum serum concentration (Tmax) of FS118

    Blood samples for serum PK analysis will be obtained (Tmax measured in hours)

    Time frame: 7 months

  5. Dose escalation: Trough serum concentration (Ctrough) of FS118 prior to the next dose

    Blood samples for serum PK analysis will be obtained (Ctrough measured in mcg/mL)

    Time frame: 7 months

  6. Dose escalation: Area under the serum FS118 concentration vs time Curve (AUC)

    Blood samples for serum PK analysis will be obtained (AUC measured in d.mcg/mL)

    Time frame: 7 months

  7. Dose escalation: Systemic Clearance (CL) of FS118

    Blood samples for serum PK analysis will be obtained (CL measured in mL/day)

    Time frame: 7 months

  8. Expansion cohort: Disease control rate as assessed by RECIST 1.1 in evaluable participants with PD-L1 and LAG-3 positive SCCHN

    Assessed by RECIST 1.1

    Time frame: 24 weeks

  9. Expansion cohort (FS118 + paclitaxel): Incidence of Treatment Emergent Adverse Events (safety and Tolerability) Incidence, severity and duration of adverse events

    Assessed by CTCAE v 5.0

    Time frame: 12 months

Secondary outcomes

  1. Dose escalation: Disease Response as assessed by RECIST 1.1 and iRECIST

    Assessed by RECIST 1.1 and iRECIST

    Time frame: 7 months

  2. Dose escalation and expansion cohort of FS118 + paclitaxel

    Incidence of FS118 immunogenicity will include ADA detection and analysis (incidence measured in titre)

    Time frame: 7 months

  3. Expansion cohort: Disease Response as assessed by RECIST 1.1 and iRECIST in all SCCHN participants

    Assessed by RECIST 1.1 and iRECIST

    Time frame: 24 months

  4. Expansion cohort: Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)

    Incidence, severity and duration of adverse events will be assessed by CTCAEv4.03

    Time frame: 12 months

  5. Expansion cohort: Maximum Serum Concentration of FS118

    Blood samples for serum PK analysis will be obtained (Cmax measured in mcg/mL)

    Time frame: 7 months

  6. Expansion cohort: Time to reach maximum serum concentration (Tmax) of FS118

    Blood samples for serum PK analysis will be obtained (Tmax measured in hours)

    Time frame: 7 months

  7. Expansion cohort: Trough serum concentration (Ctrough) of FS118 prior to the next dose

    Blood samples for serum PK analysis will be obtained (Ctrough measured in mcg/mL)

    Time frame: 7 months

  8. Expansion cohort: Area under the serum FS118 concentration vs time Curve (AUC)

    Blood samples for serum PK analysis will be obtained (AUC measured in d.mcg/mL)

    Time frame: 7 months

  9. Expansion cohort: Systemic Clearance (CL) of FS118

    Blood samples for serum PK analysis will be obtained (CL measured in mL/day)

    Time frame: 7 months

07

Study locations

12 sites
  • University of California Los Angeles (UCLA)
    Los Angeles, California 90095, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Emory Healthcare
    Atlanta, Georgia 30322, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • South Texas Accelerated Research Therapeutics
    San Antonio, Texas 78229, United States
  • CHU Bordeaux
    Bordeaux, France
  • Centre Oscar Lambret
    Lille, France
  • Centre Lyon Berard
    Lyon, France
  • La Timone
    Marseille, France
  • Centre Antoine Lacassagne
    Nice, France
08

References and documents

Publications

  • Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M. A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. Clin Cancer Res. 2023 Mar 1;29(5):888-898. doi: 10.1158/1078-0432.CCR-22-1449. PubMed 36342102 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jun 2024, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Feb 22, 2018
StartActual
Apr 16, 2018
Primary completionActual
Jun 21, 2024
CompletionActual
Jun 21, 2024
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03440437
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Apr 16, 2018
Primary completion
Jun 21, 2024
Completion
Jun 21, 2024
Last update
Jul 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion